46.58 0.00 (0.00%)
After hours: 4:18PM EDT
|Bid||46.58 x 800|
|Ask||46.59 x 800|
|Day's Range||45.94 - 46.89|
|52 Week Range||42.17 - 66.45|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 9, 2019|
|Forward Dividend & Yield||1.91 (3.96%)|
|1y Target Est||54.00|
NEW YORK (AP) — The pharmaceutical industry executive hit Tuesday with criminal charges stemming from the opioid crisis doesn't have his name on a museum wing, and his company isn't within earshot of Apple or anyone else on the Fortune 500. Even his $1.5 million paycheck was a paltry sum compared to his peers.
The U.S. government on Tuesday filed its first criminal charges against a major drug distributor and company executives over their alleged roles in fueling the nation's opioid epidemic by putting profits ahead of patients' safety. Rochester Drug Co-operative Inc (RDC), one of the 10 largest U.S. drug distributors, agreed to pay a $20 million fine and enter a five-year deferred prosecution agreement to resolve charges it turned a blind eye to thousands of suspicious orders for opioids. Two former RDC executives were also charged, including Laurence Doud, who had been its chief executive for more than 25 years.
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
DUBLIN, Ohio , April 15, 2019 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2019 on May 9 prior to the opening of trading on the New York ...
On the basis of the continued decline of pharmaceutical spending growth and external shock threats, we have lowered our economic moat ratings for AmerisourceBergen ABC , Cardinal Health CAH , and McKesson MCK to narrow from wide with a negative trend. The role of pharmaceutical distributor continues to evolve in an increasingly competitive and highly regulated environment. Scale and regulatory requirements have provided insulation to maintain share and generate market returns, but competitive pressures continue to build with declining reimbursement, healthcare consolidation, and decline in overall pharmaceutical spending growth.
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Insider Monkey finished processing more than 700 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of December 31st, 2018. What do these smart investors think about Cardinal Health, Inc. (NYSE:CAH)? Cardinal Health, Inc. (NYSE:CAH) has seen an increase in support from the world's most elite money […]
The opioid crisis in the United States is a medical and societal tragedy, but some companies are working to fight addiction.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Cardinal Health, Inc. (NYSE:CAH), a large-cap worth US$14b, comes to mind for investors seeking a strong and reliable stock i...
Moody's Investors Service ("Moody's") downgraded Owens & Minor, Inc.'s Corporate Family Rating (CFR) to B2 from B1 and the Probability of Default Rating (PD) to B2-PD from B1-PD. Moody's also downgraded the ratings on the senior secured credit facilities and notes to B2 from B1. Concurrently, Moody's affirmed the SGL-3 Speculative Grade Liquidity Rating, signifying adequate liquidity.
NEW YORK (AP) — New York is suing the billionaire family behind the company that created OxyContin, joining a growing list of state and local governments seeking to hold not only the firm but its owners accountable for the nation's opioid crisis.
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
Cardinal Health and McKesson Corporation have similar business models, but they are very different stocks. This is the case with McKesson and Cardinal Health, as well. McKesson is the more attractive stock for growth, while Cardinal Health is a high-yielding income stock.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.